ProCE Banner Activity

Challenging Cases in HIV Care: A Roundtable

In this on-demand webcast of a live roundtable, expert faculty consider the integrated approaches needed to address barriers to ART adherence and to select an effective new regimen for an older man with long-standing HIV infection, several comorbidities, and a complex treatment history with multiclass drug resistance. Then the expert panel discusses the best management strategies for a patient who is gaining excess weight on an INSTI- and TAF-containing first-line regimen.

Released: October 29, 2021

Expiration: October 28, 2022

No longer available for credit.

Share

Faculty

Babafemi Taiwo

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Rajesh Gandhi

Rajesh Gandhi, MD

Assistant Professor of Medicine
Massachusetts General Hospital and Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by

Merck Sharp & Dohme Corp.

ViiV Healthcare

Target Audience

This program is intended for pathologists and other healthcare providers who treat and manage patients with lung cancer.

Program Director Disclosure

Program Director

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV and funds for research support from Janssen.

Faculty Disclosure

Primary Author

Rajesh Gandhi, MD

Assistant Professor of Medicine
Massachusetts General Hospital and Harvard Medical School
Boston, Massachusetts

Rajesh T. Gandhi, MD, has disclosed that he has received consulting fees from Merck.

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Daniel R. Kuritzkes, MD, has disclosed that he has received funds for research support rom Atea, Gilead Sciences, Merck, Novartis, and ViiV and consulting fees from Abpro, Atea, Decoy, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Rigel, and ViiV.

Staff Disclosure

Staff

Sarah Anderson, PharmD

Scientific Director

Sarah L. Anderson, PharmD, BCACP, BCPS, FASHP, FCCP, has no relevant conflicts of interest to report.

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Additional Information

Program Medium

This program has been made available online.

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Goal


The goal of this activity is to improve participants’ knowledge of and competence in assessing biomarkers to guide the use of immune checkpoint inhibitors in the treatment of patients with lung cancer.